Patents Examined by J. Hines
-
Patent number: 8822211Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentially present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.Type: GrantFiled: June 11, 2013Date of Patent: September 2, 2014Assignee: Becton Dickinson Infusion Therapy Systems Inc.Inventors: Jean-Pierre Hermet, Isabelle Besson-Faure, Sebastien Ribault, Yann Godfrin, Anne Monnot des Angles
-
Patent number: 8642283Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.Type: GrantFiled: May 26, 2006Date of Patent: February 4, 2014Assignee: Sanford-Burnham Medical Research InstituteInventor: Robert T. Abraham
-
Patent number: 8586349Abstract: The present invention concerns a method for the detection of an analyte in a droplet of fluid comprising the steps of providing a solid phase with a hydrophobic surface comprising at least one capture zone on which at least one binding agent with affinity for the analyte is immobilized, applying said droplet to the surface of said solid phase, applying a force that makes the droplet travel along the surface of said solid phase along a predetermined path thereby allowing the droplet to repeatedly contact said binding agent on the capture zone, applying conditions wherein said analyte is allowed to bind to said binding agent and detecting a complex of analyte and binding reagent at the position of the capture zone. The effect of a moving droplet is that the reactants in the droplet are well mixed which eliminates the risk of diffusion limitation. Such advantageous mixing is not obtained with conventional assays in which the surface is continuously exposed to the liquid.Type: GrantFiled: August 6, 2001Date of Patent: November 19, 2013Assignee: Biomerieux B.V.Inventors: Thomas Augustinus Maria Beumer, Petrus Franciscus Hendrikus M. Verheijden, Hendrik Sibolt van Damme
-
Patent number: 8481054Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.Type: GrantFiled: December 28, 2006Date of Patent: July 9, 2013Assignees: The UAB Foundation, Fundacao Oswald Cruz, Instituto Adolfo LutzInventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
-
Patent number: 8409563Abstract: A purine-derived substance is produced by culturing a bacterium belonging to the genus Bacillus which is able to produce purine-derived substance and has been modified so that enzymatic activity of fructose bisphosphatase is decreased, and collecting the purine-derived substance from the medium or cells.Type: GrantFiled: October 21, 2008Date of Patent: April 2, 2013Assignee: Ajinomoto Co., Inc.Inventors: Takayuki Asahara, Kiyoshi Matsuno, Yukiko Mori
-
Patent number: 8343726Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.Type: GrantFiled: November 23, 2005Date of Patent: January 1, 2013Assignee: Techlab, Inc.Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
-
Patent number: 7993917Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: GrantFiled: August 20, 2009Date of Patent: August 9, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Samuel K. Martin
-
Patent number: 7887817Abstract: A process for preventing a protozoal disease by the administration of an alkyl phosphocholine to a human being.Type: GrantFiled: January 8, 2003Date of Patent: February 15, 2011Assignee: AEterna Zentaris GmbHInventor: Jürgen Engel
-
Patent number: 7776332Abstract: A composition for an infant formula which includes casein protein and whey protein; a method of producing the composition; use of the composition in the manufacture of a medicament or nutritional product for addressing malnutrition; and a method of addressing malnutrition which includes administering an effective amount of the composition are provided. The composition includes protein, free arginine; tryptophan and histidine, a lipid source and a carbohydrate source. In addition, the whey protein is sweet whey protein from which caseino-glyco-macropeptide has been removed.Type: GrantFiled: September 12, 2000Date of Patent: August 17, 2010Assignee: Nestec S.A.Inventors: Martinas Kuslys, Marie-Christine Secretin, Rolf Jost, Jean-Claude Maire, Olivier Ballevre, Ferdinand Haschke, Zdenek Kratky, Niklaus Meister
-
Patent number: 7771972Abstract: The present invention relates to the cloning, sequencing and analysing of a gene cluster encoding a modular polyketide synthase enzyme involved in the biosynthesis of the antitumor compound pederin. This novel cluster represents the first example of genes from an unculturable symbiont encoding the biosynthesis of a drug candidate.Type: GrantFiled: November 21, 2002Date of Patent: August 10, 2010Assignee: Rheinische Friedrich-Wilhelms-Universitaet BonnInventor: Jörn Piel
-
Patent number: 7687278Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of Streptococci mutans by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of Streptococci mutans in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and Streptococci mutans from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.Type: GrantFiled: April 13, 2006Date of Patent: March 30, 2010Assignee: GC CorporationInventor: Atsushi Tachino
-
Patent number: 7547536Abstract: A method of detecting the presence and quantity of bacterial spores, which includes adding an electrophilic alcohol and an acid anhydride to a sample, admixing the sample with a solvent, and analyzing the sample. The sample may be analyzed by injecting the mixture into a gas chromatograph equipped with a mass spectra detector.Type: GrantFiled: May 31, 2002Date of Patent: June 16, 2009Assignee: JEOL USA, Inc.Inventors: James A. Laramée, Robert B. Cody
-
Patent number: 7521187Abstract: This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.Type: GrantFiled: December 2, 2003Date of Patent: April 21, 2009Assignee: Vical IncorporatedInventor: Andrew Geall
-
Patent number: 7449340Abstract: The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI).Type: GrantFiled: August 9, 2001Date of Patent: November 11, 2008Assignee: Era-Massis, Inc.Inventors: Gil Tenne, Mark L. Levitt, Anahit Karapetian
-
Patent number: 7422849Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.Type: GrantFiled: June 3, 1999Date of Patent: September 9, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
-
Patent number: 7374765Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.Type: GrantFiled: October 1, 2004Date of Patent: May 20, 2008Assignee: Bio-Rad Laboratories, Inc.Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
-
Patent number: 7344849Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.Type: GrantFiled: July 23, 2004Date of Patent: March 18, 2008Assignee: Axis-Shield ASAInventors: Erling Sundrehagen, Lars Örning
-
Patent number: 7297529Abstract: An embodiment of the present invention provides a method for performing a lateral flow assay. The method includes depositing a sample on a test strip at an application region, detecting a first detection signal arising from the test strip in the first detection zone, and generating a baseline for the first measurement zone by interpolating between values of the detection signal outside of the first measurement zone and inside of the first detection zone. The method may include locating a beginning boundary and an ending boundary for the first measurement zone on the test strip. Additional detection zones having measurement zones may also be incorporated with the embodiment.Type: GrantFiled: August 4, 2003Date of Patent: November 20, 2007Assignee: Relia Diagnostic Systems, LLCInventors: Alan J. Polito, Richard M. Thayer, Robert K. DiNello, George H. Sierra, Dennis Nixon, Alan Phillips, Stuart Neubarth
-
Patent number: 7297551Abstract: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 ?M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 ?M of SSCrFCES inhibits the LPS-induced secretion of hTNF-? and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B.Type: GrantFiled: August 7, 2003Date of Patent: November 20, 2007Assignee: National University of SingaporeInventors: Jeak L. Ding, BoW Ho, Nguan S. Tan
-
Patent number: 7214788Abstract: Novel insect inhibitory proteins are disclosed comprising two different components, both of which are required for biological activity. Various methods of linking both components together, so that a single protein provides insect inhibitory activity, are disclosed. Also disclosed are novel Bacillus thuringiensis nucleic acid sequences encoding Coleopteran-inhibitory crystal proteins, designated tIC100 (29-kDa) and tIC101 (14-kDa). Also disclosed are methods of making and using nucleic acid sequences in the development of the transgenic plant cells containing the novel nucleic acid sequences disclosed herein.Type: GrantFiled: September 12, 2001Date of Patent: May 8, 2007Assignee: Monsanto Technology LLCInventors: Victor M. Guzov, Thomas M. Malvar, James K. Roberts, Sakuntala Sivasupramaniam